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A. Project number: 06- 02 -OS .. 6021 
Project title: To investigate the role of fetoplacental prorenin, rennin EDRF 
and Endothelins in the Toxaemia of pregnancy. 
Project leader: Dr Harbindar Jeet Singh 
Tel: 09-7655518 Fax: 09-7653370 
B. Summary for fviPKSN Report (For publication in the Annual MPKSN Report, 
please summarise the project objectives, significant results achieved, research 
approach and team structure) 
The main objective of the study was to investigate the role ofEndothelin-1, EDRF, 
renin and prorenin in fetoplacental tissues. The precise pathogenesis of pre-eclampsia 
is still unknown but there is a generally held view that placental hypoperfusion, 
secondary to some vaso-active substance, may be responsible for this disease entity. 
Endothelin- I is a very powerful vasoconstrictor whereas EDRF is a vasodilator. 
Renin, through activation of the localized renin angiotensin system, may also work as 
a vasoconstrictor. Prorenin is being considered by some as not only a precursor of 
renin but, it by itself: as a vasodilator. We hypothesise that there probably exists an 
imbalance between the various vasodilator and vasoconstrictor substances in the 
placenta, more in favour of vasoconstrictors. This imbalance may be responsible for 
the placental vasoconstriction and consequently placental hypoperfusion. 
Our observations reveal significantly higher levels of endothelin-1 in fetoplacental 
tissues from women with pre-eclampsia We did not find any significant differences 
in renin activity or renin concentration in the fetoplacental tissues between the two 
groups. Total renin however was significantly higher in tissues from women with 
pre-eclampsia We were unable to measure EDRF in this study and therefore would 
fmd it difficult to precisely state the significance of these observations. But in 
another separate study, we have observed a lowered kallikrien-kinin (KKS)activity in 
placenta from women with pre-eclampsia KKS has vasodilator properties. It is 
possible therefore that EDRF activity may be similarly lowered. Nitric oxide 
synthetase activity has been observed to be lower in placentae from women with pre-
eclampsia 
From our observations it may be concluded, that there exists an abnormality in the 
expression of endothelin in the placenta ~d ~ over production of this peptid~ may 
be responsible for some of the .vasoconstriction and cons~uently hyp?p~ston ~f 
the placenta The raised proremn may be a response to tht~ vasoconstnctton . but _1ts 
vasodilator response may be blunted. However more studtes are needed to tdenttfy 
the cellular sources of these peptides in the placenta before it can be conclusively 
established that over production of endothelin-1 may indeed be the primary 
abnormality, 
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C. Objectives achievement 
• Original project objectives (Please state the specific project objectives as 
described in Saction IT of the Application Form) 
1) To measure renin activity in feto-placental tissues 
2) To measure renin concentration and feto-placental tissues 
3) To measure prorenin cncentration in feto-palcental tissues 
4) To measure endothelin-1 concentration in fetoplacental tissues 
5) To measure EDRF concentration in fetoplacental tissues 
6) Endothelin-1 and EDRF production in HUVEC 
• Objectives Achieved (Please state the extent to which the project objectives 
were achieved) 
Objectives 1 - 4 achieved 
• Objectives not achieved (Please identifY the objectives that were not achieved 
and give reasons) 
Objectives 4 -5 not achieved 
Reason- Insufficient funds approved. 
D. Technology Transfer/Commercialisation Approach (Please describe the 
approach planned to transfer/commercialise the results of the project) 
May-96 
Publication of the findings in international journals. It has added another 
aspect to the possible pathogenesis of pre-eclampsia. 
A paper entitled " Endothe/in-1 in feto-placenta/ tissues from normotensive 
women and women with pre-eclampsia" has just been accepted for 
publication in Acta Obstetricia et Gynecologica Scandinavica 
A second paper entitled 'Total rennin in fetoplacental tissues of 
normotensive women and women with Pre-eclampsia" is currently under 
preparation and shall be submitted for publication to an international jownal 
shortly 
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E. Benefits of the Project (Please identi1}r the actual benefits ansing from the project as 
defined in Scetion m of the Application Form for examples of outputs, organisational 
outcomes and sectoral/national impacts, please refer to Section m of the Guidelines for the 
Application of R&D Ftmding under IRP A) 
May-96 
• Outputs of the project and potential beneficiaries (Please describe as 
specifically as possible the outputs achieved and provide an assessment of their 
significance to users) 
Our findings of raised endothelin-1 and total renin levels in the placentae of women with pre-
eclampsia suggest of a possible imbalance of vaso-active factors in the placenta They seem 
to suggest of an imbalance that is more in favour of vasoconstriction and may be responsible 
for the placental hypo perfusion which underlies the pathophysiology of preeclampsia Our 
observations have certainly highlighted the need to clearly examine the role of vaso-active 
substances in the placental vasculature. An abnonnal expression of vaso-constrictors coud 
result in placental vascular constriction and consequently hypoperfusion. 
This study identifies the possible vaso-constrictors and it is possible endothelin-1 blockers 
may have a role in the management of pre-eclampsia 
• Organisational Outcomes (Please describe as specifically as possible the 
organisational benefits arising from the project and provide an assessment of their 
significance) 
This study has helped establish our department as another center for 
the study of hypertension in pregnancy and pre-eclampsia 
e National Impacts (If known at this point in time, please describe as specifically 
as possible the potential sect~r~~tional benefits arising from the project and 
provide an assessment of thetr significance 
3 End of Project Report 
D. Assessment of project Structure 
• Project Team (Please provide an assessment of how the project team performed 
and highlight any significant departures from plan in either structure or actual man 
days utilised 
Overall the project team performed well. The only disappointment 
was that we were unable to fully cany out all the objectives because of 
insufficient funds and the distribution of the funds over the three years. 
• CoUaborations (Please describe the nature of collaborations with other research 
organisation and/or industry) 
None at the moment 
G. Assessment of Research Approach (Please highlight the main steps actually 
performed and indicate any major departure from the planned approach or any major difficulty 
encOtmtered) 
H. 
May-96 
I}O 
The approach was as planned and there we~epartures from it. 
Assessment of the Project Schedule (Please make any relevant comment regarding 
the actual duration of the project and highlight any significant variation .from plan) 
No real variations. The project went on as planned 
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I. Assessment of Project Costs (Please comment on the appropriateness of the original 
budget and highlight any major departure from the planned budget) 
The budget requested was appropriate for the objectives outlined However the fimds 
approved were not sufficient to realize all the objectives. 
J. Additional Project Funding Obtained (In case of involvement of other funding 
sources, please indicate the source and total fimding provided) 
None 
K. Other Remarks (Please include any other comment which you feel is relevant for the 
evaluation of this project) 
--
Signature: 
May-6 5 End of Project Report 
Maklumat Tambahan Yang Diperlukan 
Teclmology Transfer/Commercialisation Approach (Please describe the approach 
planned to transfer/ commercialise the results of the project) 
Patent (Please state full title of the patent by giving the patent number or application 
number) 
NONE 
Publication pertaining to the research finding 
(a) Report/Conference Paper 
(b) 
1. ' The distribution of endothelin in feto-placental tissues of women 
with pregnancy-induced hypertension" 3rd National Conference on 
Medical Sciences 25-26 May 1997, Kota Bharu, Kelantan 
2. "Total rennin concentration in fetoplacental tissues from women 
with pregnancy-induced hypertension" 4th National Conference on 
Medical Sciences 8-9 June 1998, Kota Bharu Kelantan 
3. "Renin in fetoplacental membranes of normotensive pregnant 
women and women with pre·eclampsia" 4th Congress of the 
Federation of Asia-Oceania Physiological Societies, 27 Sept - 1 Oct 
1998, Brisbane Australia 
4. Endothelin-1 in feto-placental tissues from Normotensive pregnant 
women and women with pre-eclampsia. 15th Scientific Meeting of 
the Malaysia Society of Pharmacology and Physiology 8-9th May 
2000, Kota Bharu Kelantan 
Journal Publication (Use only the standard accepted abbreviations for 
Joumol titles, If there are none give full Joumal title) 
1. HJ Singh, A Rahman, ET Lannie, A Nila " Endothelin-1 in feto-
placental tissues :from normotensive pregnant women and women 
with pre-eclampsia" Acta Obs & Gyn. Scand. (In press) 
2. HJ Singh, A Rahman, ET Larmie, A Nila " Prorenin, total renin 
and renin activity in feto-placental tissues from nonnotensive 
pregnant women and women with pre-eclampsia" (Under 
preparation) 
(c) Others: 
-
e Post Graduates (Who graduated or who are still participating in the project) 
Student Name & Year of Thesis Title PhD/MSc Year of 
Registration/Nationality Completion 
.-
NO"t\1~ ~ 
~ 
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• No. of Research Assistants or Officers funded by the project: 
(a) Research Officers: 1 (one) (b) Research Assistants: None 
• Collaboration (Please describe the nature of collaborations with other 
research organizations and/or industry) 
Institutions: 
(a) Local Institutions 
--
(b) International Institutions: 
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